Chardan Capital Markets analyst Keay Nakae downgraded Arbutus Biopharma (NASDAQ: ABUS) from Buy to Neutral.The analyst commented, "Yesterday, Arbutus announced ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE